HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.
about
Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteHIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP TrimersGlycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortDiversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization BreadthEffects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development.Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
P2860
Q27022652-7DCAEB67-7EB9-4EFE-AF04-7715FEB37638Q27025177-25620871-A9F6-413E-A72F-767F14A4AB58Q27319450-73797DEE-4A34-40A1-B8D4-3D47A80374C8Q33753573-0FE02562-08B6-483D-9117-3752349FFC7AQ33907694-DDA53FCB-D879-4012-829A-A4B9018A0C11Q34555891-7474614B-F3AE-4B49-80B7-102E7D41CFB8Q34594513-AA883F32-768E-438D-BC2E-251436386BBEQ35894094-1B8B54BB-B5F0-45D1-A1B1-0AEAE6BA33E1Q36194234-FA0A3A17-0D34-4EAE-8150-E049B2572D44Q36303368-7D92ACF8-BE05-49AE-8294-F6C9AEB9772FQ37069837-C33131A4-7CB1-459B-B080-79CBB55D28D9Q37073506-E8D8246A-3062-4EC9-88E3-2C5D38EE4CDDQ39108751-970AD10C-2834-44FD-B974-FDA9C50F94C0Q41611835-F5DAB59C-F512-477D-BDD2-992215BBACD3Q56974226-E64ECFF5-FB9E-4C68-BFF5-DEC4E4F1949B
P2860
HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HIV-1 envelope glycoprotein si ...... eactive neutralizing activity.
@en
HIV-1 envelope glycoprotein si ...... eactive neutralizing activity.
@nl
type
label
HIV-1 envelope glycoprotein si ...... eactive neutralizing activity.
@en
HIV-1 envelope glycoprotein si ...... eactive neutralizing activity.
@nl
prefLabel
HIV-1 envelope glycoprotein si ...... eactive neutralizing activity.
@en
HIV-1 envelope glycoprotein si ...... eactive neutralizing activity.
@nl
P2093
P2860
P356
P1433
P1476
HIV-1 envelope glycoprotein si ...... reactive neutralizing activity
@en
P2093
Brigitte D Boeser-Nunnink
Hanneke Schuitemaker
Jaap Heringa
Linda W E Rijsdijk
Rogier W Sanders
Tom L G M van den Kerkhof
Zelda Euler
P2860
P2888
P356
10.1186/1742-4690-10-102
P577
2013-09-23T00:00:00Z
P5875
P6179
1043888557